JP2019521659A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521659A5 JP2019521659A5 JP2018561967A JP2018561967A JP2019521659A5 JP 2019521659 A5 JP2019521659 A5 JP 2019521659A5 JP 2018561967 A JP2018561967 A JP 2018561967A JP 2018561967 A JP2018561967 A JP 2018561967A JP 2019521659 A5 JP2019521659 A5 JP 2019521659A5
- Authority
- JP
- Japan
- Prior art keywords
- genome editing
- editing complex
- complex according
- peptide
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000010362 genome editing Methods 0.000 claims description 130
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 73
- 239000002105 nanoparticle Substances 0.000 claims description 59
- 210000004027 cell Anatomy 0.000 claims description 39
- 108091033319 polynucleotide Proteins 0.000 claims description 35
- 102000040430 polynucleotide Human genes 0.000 claims description 35
- 239000002157 polynucleotide Substances 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 32
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 108020005004 Guide RNA Proteins 0.000 claims description 21
- 210000000170 cell membrane Anatomy 0.000 claims description 20
- 230000000149 penetrating effect Effects 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims description 16
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 238000012986 modification Methods 0.000 claims description 14
- 230000004048 modification Effects 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 8
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 6
- 102100031780 Endonuclease Human genes 0.000 claims description 6
- 108010042407 Endonucleases Proteins 0.000 claims description 6
- 101710185494 Zinc finger protein Proteins 0.000 claims description 6
- 102100023597 Zinc finger protein 816 Human genes 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 230000006798 recombination Effects 0.000 claims description 6
- 238000005215 recombination Methods 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 6
- 102100034343 Integrase Human genes 0.000 claims description 5
- 108010061833 Integrases Proteins 0.000 claims description 5
- 101710163270 Nuclease Proteins 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- JPSHPWJJSVEEAX-OWPBQMJCSA-N (2s)-2-amino-4-fluoranylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC([18F])C(O)=O JPSHPWJJSVEEAX-OWPBQMJCSA-N 0.000 claims description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 108091033409 CRISPR Proteins 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 claims description 2
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 2
- 210000003714 granulocyte Anatomy 0.000 claims description 2
- 210000003630 histaminocyte Anatomy 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 230000002103 transcriptional effect Effects 0.000 claims description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 208000028782 Hereditary disease Diseases 0.000 description 2
- 208000024556 Mendelian disease Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 108091008023 transcriptional regulators Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000012220 Member 14 Tumor Necrosis Factor Receptors Human genes 0.000 description 1
- 108010066154 Nuclear Export Signals Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical class OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021184056A JP7379447B2 (ja) | 2016-05-27 | 2021-11-11 | ゲノム編集分子の細胞内送達のためのペプチドおよびナノ粒子 |
| JP2023169638A JP2023165986A (ja) | 2016-05-27 | 2023-09-29 | ゲノム編集分子の細胞内送達のためのペプチドおよびナノ粒子 |
| JP2025079827A JP2025118829A (ja) | 2016-05-27 | 2025-05-12 | ゲノム編集分子の細胞内送達のためのペプチドおよびナノ粒子 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662342823P | 2016-05-27 | 2016-05-27 | |
| US62/342,823 | 2016-05-27 | ||
| US201662394140P | 2016-09-13 | 2016-09-13 | |
| US62/394,140 | 2016-09-13 | ||
| US201762477357P | 2017-03-27 | 2017-03-27 | |
| US62/477,357 | 2017-03-27 | ||
| PCT/US2017/034862 WO2017205846A1 (en) | 2016-05-27 | 2017-05-26 | Peptides and nanoparticles for intracellular delivery of genome-editing molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021184056A Division JP7379447B2 (ja) | 2016-05-27 | 2021-11-11 | ゲノム編集分子の細胞内送達のためのペプチドおよびナノ粒子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019521659A JP2019521659A (ja) | 2019-08-08 |
| JP2019521659A5 true JP2019521659A5 (enExample) | 2020-07-02 |
Family
ID=59239942
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561967A Pending JP2019521659A (ja) | 2016-05-27 | 2017-05-26 | ゲノム編集分子の細胞内送達のためのペプチドおよびナノ粒子 |
| JP2021184056A Active JP7379447B2 (ja) | 2016-05-27 | 2021-11-11 | ゲノム編集分子の細胞内送達のためのペプチドおよびナノ粒子 |
| JP2023169638A Withdrawn JP2023165986A (ja) | 2016-05-27 | 2023-09-29 | ゲノム編集分子の細胞内送達のためのペプチドおよびナノ粒子 |
| JP2025079827A Pending JP2025118829A (ja) | 2016-05-27 | 2025-05-12 | ゲノム編集分子の細胞内送達のためのペプチドおよびナノ粒子 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021184056A Active JP7379447B2 (ja) | 2016-05-27 | 2021-11-11 | ゲノム編集分子の細胞内送達のためのペプチドおよびナノ粒子 |
| JP2023169638A Withdrawn JP2023165986A (ja) | 2016-05-27 | 2023-09-29 | ゲノム編集分子の細胞内送達のためのペプチドおよびナノ粒子 |
| JP2025079827A Pending JP2025118829A (ja) | 2016-05-27 | 2025-05-12 | ゲノム編集分子の細胞内送達のためのペプチドおよびナノ粒子 |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP3464323B1 (enExample) |
| JP (4) | JP2019521659A (enExample) |
| CN (2) | CN117431234A (enExample) |
| AU (2) | AU2017268842B2 (enExample) |
| CA (1) | CA3025523A1 (enExample) |
| ES (1) | ES2901215T3 (enExample) |
| MX (2) | MX388294B (enExample) |
| WO (1) | WO2017205846A1 (enExample) |
| ZA (1) | ZA201807869B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3665285A4 (en) * | 2017-08-10 | 2021-08-11 | Aadigen, LLC | PEPTIDES AND NANOPARTICLES FOR INTRACELLULAR VIRUS ADMINISTRATION |
| JP7395483B2 (ja) * | 2017-10-16 | 2023-12-11 | アーディジェン， エルエルシー | ｍＲＮＡの細胞内送達のためのペプチドおよびナノ粒子 |
| FR3081169B1 (fr) * | 2018-05-15 | 2020-06-19 | Messenger Biopharma | Substitution de la coiffe des arn messagers par deux sequences d'arn introduites a leur extremite 5' |
| WO2019237384A1 (zh) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | 用于敲除人CDw137基因的gRNA序列及其应用 |
| WO2019237387A1 (zh) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | 用于敲除人ACT35基因的gRNA序列及其应用 |
| CN111363013B (zh) * | 2018-12-25 | 2021-11-19 | 深圳先进技术研究院 | 多组分纳米颗粒簇的构建方法 |
| GB201902648D0 (en) | 2019-02-27 | 2019-04-10 | Cyca Oncosolutions Ltd | Cell membrane penetrating conjugates |
| US12357695B2 (en) | 2019-04-17 | 2025-07-15 | Aadigen, Llc | Peptides and nanoparticles for intracellular delivery of molecules |
| CN109880891B (zh) * | 2019-04-22 | 2021-07-30 | 上海交通大学 | 基于核酸酶偶联pcr原理富集低丰度dna突变的检测技术体系及应用 |
| CN113784731A (zh) * | 2019-05-07 | 2021-12-10 | 洛桑联邦理工学院 | Fmrp及癌症治疗 |
| CN110638789A (zh) * | 2019-10-31 | 2020-01-03 | 南开大学 | 一种可实现肿瘤靶向递送核糖核蛋白复合物的纳米粒子的制备方法和应用 |
| EP4139454A4 (en) * | 2020-04-24 | 2025-07-30 | Aadigen Llc | CANCER TREATMENT COMPOSITIONS WITH DEMUTATIONS AND THEIR USES |
| CN116724059A (zh) * | 2020-07-24 | 2023-09-08 | 阿迪根有限公司 | 用于治疗病毒感染的组合物和方法 |
| KR102500873B1 (ko) * | 2021-02-03 | 2023-02-17 | 한국과학기술연구원 | 자연살해세포 특이적 CRISPR/Cas 시스템을 위한 융합 단백질 및 이의 용도 |
| US20250092459A1 (en) * | 2021-07-26 | 2025-03-20 | Imperial College Innovations Limited | Nanozyme-catalysed detection of nucleic acids |
| WO2025059215A1 (en) | 2023-09-12 | 2025-03-20 | Aadigen, Llc | Methods and compositions for treating or preventing cancer |
| WO2025090926A1 (en) * | 2023-10-26 | 2025-05-01 | The Penn State Research Foundation | Ultrasound-sensitive peptide particles with surface-bound gene editing tools for spatially resolved molecule delivery |
| CN119119204B (zh) * | 2024-11-11 | 2025-03-18 | 南昌大学 | 温敏特异性多肽和基于温差特异性无损分离外泌体的方法 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
| US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
| US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
| WO1994010958A1 (en) | 1992-11-13 | 1994-05-26 | Mitchell Winalee G | Absorbent including super absorbent and capacity monitor |
| WO1996040958A1 (en) | 1995-06-07 | 1996-12-19 | Baylor College Of Medicine | Nucleic acid transporters for delivery of nucleic acids into a cell |
| US6451995B1 (en) | 1996-03-20 | 2002-09-17 | Sloan-Kettering Institute For Cancer Research | Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods |
| WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
| US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
| US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
| DE60023936T2 (de) | 1999-12-06 | 2006-05-24 | Sangamo Biosciences Inc., Richmond | Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen |
| US6689558B2 (en) | 2000-02-08 | 2004-02-10 | Sangamo Biosciences, Inc. | Cells for drug discovery |
| WO2001094944A2 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| ATE338124T1 (de) | 2000-11-07 | 2006-09-15 | Hope City | Cd19-spezifische umgezielte immunzellen |
| US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| DE602005011943D1 (de) | 2004-04-08 | 2009-02-05 | Sangamo Biosciences Inc | Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen |
| AU2005233550B2 (en) | 2004-04-08 | 2010-11-18 | Sangamo Therapeutics, Inc. | Treatment of neuropathic pain with zinc finger proteins |
| US7514530B2 (en) | 2004-04-26 | 2009-04-07 | Centre National De La Recherche Scientifique | Peptide carrier for delivering siRNA into mammalian cells |
| US7579318B2 (en) | 2005-12-06 | 2009-08-25 | Centre De La Recherche De La Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| EP2856876B1 (en) | 2007-03-30 | 2018-01-31 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| DE102008036364A1 (de) | 2008-08-05 | 2010-02-18 | Khs Ag | Verfahren zum Herstellen von Behälterzellen |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| US8889394B2 (en) | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
| CN103025344B (zh) | 2010-05-17 | 2016-06-29 | 桑格摩生物科学股份有限公司 | 新型dna-结合蛋白及其用途 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CN110200997A (zh) | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| WO2012137036A1 (en) | 2011-04-04 | 2012-10-11 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| ES2687954T3 (es) | 2011-11-11 | 2018-10-30 | Fred Hutchinson Cancer Research Center | Inmunoterapia de linfocitos T dirigidos a ciclina A1 contra el cáncer |
| EP3594245A1 (en) | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| RU2018130123A (ru) | 2012-05-03 | 2018-11-07 | Фред Хатчинсон Кансэр Рисёч Сентер | Клетка, экспрессирующая t-клеточный рецептор (tcr), для применения в клеточной иммунотерапии |
| SI3401400T1 (sl) * | 2012-05-25 | 2019-10-30 | Univ California | Postopki in sestavki za RNA usmerjeno modifikacijo tarčne DNA in za RNA usmerjeno modulacijo prepisovanja |
| IL293944A (en) | 2012-08-20 | 2022-08-01 | Hutchinson Fred Cancer Res | Method and preparations for cellular immunotherapy |
| CN104853766A (zh) | 2012-10-02 | 2015-08-19 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| WO2014053879A1 (en) * | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2014053880A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2014053881A1 (en) * | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2014053882A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| SG11201503059XA (en) * | 2012-10-23 | 2015-06-29 | Toolgen Inc | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
| CA3109801C (en) | 2013-08-22 | 2024-01-09 | Andrew Cigan | Plant genome modification using guide rna/cas endonuclease systems and methods of use |
| US9526784B2 (en) * | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| CA2933134A1 (en) * | 2013-12-13 | 2015-06-18 | Cellectis | Cas9 nuclease platform for microalgae genome engineering |
| WO2016073433A1 (en) * | 2014-11-06 | 2016-05-12 | E. I. Du Pont De Nemours And Company | Peptide-mediated delivery of rna-guided endonuclease into cells |
| LT3237436T (lt) * | 2014-12-24 | 2019-09-25 | Aadigen, Llc | Peptidai ir nanodalelės, skirti molekulių įvedimui į ląstelę |
-
2017
- 2017-05-26 WO PCT/US2017/034862 patent/WO2017205846A1/en not_active Ceased
- 2017-05-26 JP JP2018561967A patent/JP2019521659A/ja active Pending
- 2017-05-26 ES ES17733918T patent/ES2901215T3/es active Active
- 2017-05-26 CN CN202311385196.6A patent/CN117431234A/zh active Pending
- 2017-05-26 EP EP17733918.1A patent/EP3464323B1/en active Active
- 2017-05-26 MX MX2018014599A patent/MX388294B/es unknown
- 2017-05-26 CA CA3025523A patent/CA3025523A1/en active Pending
- 2017-05-26 EP EP21170389.7A patent/EP3910059A1/en active Pending
- 2017-05-26 CN CN201780045854.3A patent/CN109689677B/zh active Active
- 2017-05-26 AU AU2017268842A patent/AU2017268842B2/en active Active
-
2018
- 2018-11-21 ZA ZA2018/07869A patent/ZA201807869B/en unknown
- 2018-11-27 MX MX2021014704A patent/MX2021014704A/es unknown
-
2021
- 2021-11-11 JP JP2021184056A patent/JP7379447B2/ja active Active
-
2022
- 2022-07-21 AU AU2022206789A patent/AU2022206789B9/en active Active
-
2023
- 2023-09-29 JP JP2023169638A patent/JP2023165986A/ja not_active Withdrawn
-
2025
- 2025-05-12 JP JP2025079827A patent/JP2025118829A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521659A5 (enExample) | ||
| ES2743188T3 (es) | Péptidos y nanopartículas para el suministro intracelular de moléculas | |
| US20200095605A1 (en) | Compositions and methods for nucleic acid and/or protein payload delivery | |
| EP3080260B1 (en) | Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes | |
| US20230323401A1 (en) | Methods and compositions for genome editing | |
| JP7471289B2 (ja) | 抗ｌｉｖ１免疫細胞癌療法 | |
| US20250101425A1 (en) | Nanoparticles functionalized with gene editing tools and related methods | |
| JP2024122981A (ja) | ゲノム編集方法及び組成物 | |
| JP2022529784A (ja) | 分子を細胞内送達するためのペプチドおよびナノ粒子 | |
| CA3181170A1 (en) | Compositions for treating cancer with kras mutations and uses thereof | |
| WO2020223705A2 (en) | Methods and compositions for diagnostically-responsive ligand-targeted delivery of therapeutic agents | |
| JP2025518552A (ja) | 細胞を操作するための組成物及び方法 | |
| Futami et al. | Design of cytotoxic ribonucleases by cationization to enhance intracellular protein delivery | |
| US20230332181A1 (en) | Conjugate systems and methods of use thereof | |
| WO2025261493A1 (zh) | 通过表观编辑靶向调节pcsk9的方法及其用途 | |
| JP2023538138A (ja) | ナノ粒子種基材のための組成物及び方法 | |
| WO2020112195A1 (en) | Compositions, technologies and methods of using plerixafor to enhance gene editing |